Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

NCT06435858 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

Cantonal Hospital Graubuenden

Collaborators

[object Object]